Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Genprex Inc GNPX

Healthcare Biotechnology
Genprex, Inc. is a clinical-stage gene therapy company. The Company is focused on the development of gene-based therapies for patients with unmet medical needs. The Company's lead oncology drug candidate, REQORSA Immunogen therapy drug (quaratusugene ozeplasmid), is being developed to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The active agent in REQORSA is a... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GNPX)

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

PR Newswire April 9, 2024

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

PR Newswire April 3, 2024

Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System

PR Newswire April 2, 2024

Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PR Newswire March 22, 2024

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PR Newswire March 19, 2024

Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

PR Newswire March 12, 2024

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

PR Newswire March 6, 2024

Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

PR Newswire February 7, 2024

Genprex to Present at Upcoming BIO CEO & Investor Conference

PR Newswire February 6, 2024
View More News ››

Opinion & Analysis (NDAQ:GNPX)

Genprex Shares Soar 250% on FDA Fast Track Designation for Lung Cancer Drug

Streetwise Reports January 22, 2020
View More Opinion ››

Bullboard Posts (NDAQ:GNPX)

GNPX ...on watch NR

No vol
Iseneschal - March 6, 2024

Genprex to Present at Upcoming BIO CEO & Investor Conference

Just In: $GNPX Genprex to Present at Upcoming BIO CEO & Investor ConferenceGenprex to Present at Upcoming BIO CEO @ Investor...
whytestocks - February 6, 2024

GNPX.... Very low volume...price action is trending higher

Looks like Mr. M is going to buy my sub $6 paper....Thanks Mr. M Cheers !
Iseneschal - February 5, 2024

GNPX....say goodbye to Hollywood

It's all over now
Iseneschal - February 5, 2024

RE:GNPX...just to prove my point ; )

5 minutes later 1,321,855 shs traded.....last at $6.10  in 5 minutes there was a volume of 1,118 shs Wow
Iseneschal - February 5, 2024

GNPX...just to prove my point ; )

At 9:13 a.m pst there was 1,320,737 shs traded.....last at $6.07 I will update after 5 min Keep doing your magic Mr. Maggot
Iseneschal - February 5, 2024
View more Bullboard ››

Adventus Mining Corp.

Adventus Mining Corp.

Adventus Mining Corporation is a copper-gold exploration and development company. Its Curipamba project comprises seven ...
View More »